A detailed history of Nikko Asset Management Americas, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Nikko Asset Management Americas, Inc. holds 10,362,803 shares of RXRX stock, worth $80.9 Million. This represents 1.03% of its overall portfolio holdings.

Number of Shares
10,362,803
Previous 9,203,780 12.59%
Holding current value
$80.9 Million
Previous $90.7 Million 13.85%
% of portfolio
1.03%
Previous 0.87%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

BUY
$9.13 - $15.52 $10.6 Million - $18 Million
1,159,023 Added 12.59%
10,362,803 $103 Million
Q4 2023

Feb 08, 2024

BUY
$5.09 - $10.79 $28.9 Million - $61.3 Million
5,680,656 Added 161.24%
9,203,780 $90.7 Million
Q3 2023

Nov 09, 2023

BUY
$6.59 - $15.86 $17.7 Million - $42.6 Million
2,685,724 Added 320.72%
3,523,124 $27 Million
Q2 2023

Aug 14, 2023

BUY
$4.56 - $9.94 $1.53 Million - $3.33 Million
335,423 Added 66.82%
837,400 $6.26 Million
Q1 2023

May 03, 2023

BUY
$6.42 - $9.64 $304,661 - $457,466
47,455 Added 10.44%
501,977 $3.35 Million
Q4 2022

Feb 13, 2023

SELL
$7.16 - $12.7 $259,320 - $459,968
-36,218 Reduced 7.38%
454,522 $3.5 Million
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $711,269 - $1.24 Million
90,839 Added 22.72%
490,740 $5.16 Million
Q2 2022

Aug 04, 2022

SELL
$5.04 - $9.26 $77,449 - $142,298
-15,367 Reduced 3.7%
399,901 $3.24 Million
Q1 2022

May 06, 2022

BUY
$6.16 - $18.03 $285,047 - $834,320
46,274 Added 12.54%
415,268 $2.82 Million
Q4 2021

Feb 08, 2022

SELL
$16.14 - $21.86 $648,828 - $878,772
-40,200 Reduced 9.82%
368,994 $6.32 Million
Q3 2021

Nov 09, 2021

BUY
$19.03 - $41.33 $3.3 Million - $7.16 Million
173,348 Added 73.5%
409,194 $8.59 Million
Q2 2021

Aug 09, 2021

BUY
$18.0 - $37.42 $4.25 Million - $8.83 Million
235,846 New
235,846 $8.61 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.41B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Nikko Asset Management Americas, Inc. Portfolio

Follow Nikko Asset Management Americas, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nikko Asset Management Americas, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nikko Asset Management Americas, Inc. with notifications on news.